Windtree Therapeutics (OTCMKTS:WINT) Downgraded by ValuEngine
Shares of WINT stock opened at $4.01 on Thursday. The company has a quick ratio of 0.64, a current ratio of 0.64 and a debt-to-equity ratio of 0.28. The stock has a 50-day moving average of $3.94 and a 200-day moving average of $4.27. Windtree Therapeutics has a one year low of $2.05 and a one year high of $5.35.
Windtree Therapeutics (OTCMKTS:WINT) last announced its quarterly earnings results on Wednesday, August 14th. The biotechnology company reported ($0.20) EPS for the quarter. The company had revenue of $0.16 million during the quarter. Windtree Therapeutics had a negative net margin of 3,548.97% and a negative return on equity of 65.66%.
Windtree Therapeutics, Inc, a biotechnology company, focuses on developing surfactant therapies for respiratory diseases and other potential applications. Its proprietary technology platform includes a synthetic peptide-containing surfactant (KL4 surfactant) that is structurally similar to endogenous pulmonary surfactant and drug-delivery technologies being developed to enable the noninvasive administration of aerosolized KL4 surfactant.
Featured Article: What is a dead cat bounce?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Windtree Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Windtree Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.